Don't miss it #LCAM25 event @Unispital_USZ @CCCZ_USZ Update on #NSCLC!

🚨 Registration reminder! Join us in Milan, Italy 21–22 Nov 2025 for the 2nd ESTS Italian Chapter Meeting — a key event for thoracic surgeons across Italy & Europe. Register here https://t.co/iXorLRfmXP Standard fee: €70 Residents: Free of charge #ESTS #ThoracicSurgery

💡Extended resection in T4 NSCLC sometimes requires a meticulously prepared surgical setting — for example, preoperative aortic stenting in cases with cT4 aortic wall involvement. It is essential to plan such measures well in advance and within a multidisciplinary framework. I’m

We are hiring ! Junior faculty position - German B2 needed

Thank you Dr Raphaël Bueno for jumping in and presenting our perspective about mesothelioma surgery #IMIG25 and where we go next after MARS2 =>more research to better understand PM heterogeneity =>Phase II trials combining surgery with new therapies and better selected

Lung Cancer in Nonsmoking Individuals, Review @JAMA_current 🌟 15–20% of lung cancers occur in never smokers (<100 cigarettes lifetime) A biologically distinct disease, driven by oncogenic alterations rather than tobacco carcinogens 🚬 https://t.co/vrOV4Mg5Me

🆙 #ESMO25 🇩🇪 🔥#LCSM Mini Oral, non mets ☑️ALINA: Updated from phase III adjuvant alectinib vs chemotherapy in pts with early-stage ALK+ NSCLC 🎯DFS IB-IIIA HR 0.35 (95%CI 0.23–0.54), OS HR 0.40 (95%CI 0.12–1.32) 🎙️ Dr. Rafal Dziadziuszko @OncoAlert @myESMO @Larvol

👏 Thank you Dr. Gian-Marco Monsch for stepping in at #ESMO25 to present on Surgery for Local Relapse after Curative-Intent Multimodality Treatment. Discussed this under-researched, important topic with @Piuchagarrido , @ogarrieta , Dr. Suresh Senan, @DrSanjayPopat &

Definitely disruptive - nearly 70% turned into resectable stage - curious to see the details

Definitely wow!

Missing #ESMO25 due to a sports injury 🏥—definitely not how I planned to spend the week .. Excited to see data being presented from 📌 MDT Bridge chemo IO in borderline resectable Scenario @MartinReck2 : => borderline group proceeded to resection in 70%! 🚨NorthStar- pts

Real world outcomes with neoadjuvant osimertinib and/or chemotherapy in EGFR NSCLC @LungCaJournal from Dr. @ChaftJamie. Noted 17% pCR with osimertinib (none with chemotherapy), MPR 44% osimertinib, 0% chemo, 10% osimertinib + chemo. https://t.co/5x8UNoWwT9

A team of surgeons from Shanghai Pulm Hospital describes a large series of "unresectable" patients (n=278) who underwent neoadj chemo/ICI & surgery. Remarkable results - comparable to "resectable" patients. Challenges paradigm of need for upfront decision on resectability.

I brought the big heels to share what might be the biggest challenge for people in treatment. As Dr. David Carbone said, "I told a patient she was cured, she said, 'Oh, shit, I spent all my money.'" Patients are a vulnerable population in the US, especially now, we can't think

🚨 Check our Top 10 #LungCancer abstracts for @myESMO 2025! We’ve hand-picked the must-see sessions with times, rooms & presenters 🔑 📅 Stay on track in Berlin and simply import these directly to your calendar by clicking this link: 👉 https://t.co/3zdKv9un4U Which lung

Congratulations 👏 @BiancBattilana for presenting our two highly complex cases @EuroRespSoc - good outcome only possible with good MD teamwork 💪

💬 Step into the IASLC’s new networking hub to collaborate and connect with fellow thoracic oncology experts. 🤝 🔗 More details in ILCN: https://t.co/rSORKHkkSs #LCSM

Just returned home from another great #ITSOS2025 meeting organized by @JonesDavid2013 and an amazing Programm committee and the top @AATSHQ team🤩 special dresscode 👟 only - loved it! And on top supports our next generation with the Dr Patterson Mentorship program🙌

Find yourself a few surgical besties #ITOS2025 by @AATSHQ with @IsaOpitz

Thanks for sharing Gavitt — necessity of pneumonectomy should not disqualify for patients from neoadjuvant. #itsos2025